Benjamin J. Zeskind - 15 Feb 2023 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol
IMRX
Transactions as of
15 Feb 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 15:16:03 UTC
Previous filing
27 Dec 2022
Next filing
09 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMRX Stock Option Award $0 +352,244 $0.000000 352,244 15 Feb 2023 Class A Common Stock 352,244 $4.25 Direct F1
transaction IMRX Stock Option Award $0 +21,756 +6.2% $0.000000 374,000 15 Feb 2023 Class A Common Stock 21,756 $4.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
F2 The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.